drugset / Trial / NCT00763347
Efficacy and Safety Study of SYR-619 in Treating Subjects With Type 2 Diabetes Mellitus
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine the efficacy and safety of SYR-619, once daily (QD), in subjects with type 2 diabetes mellitus who have not achieved glycemic control with diet and exercise, or by taking metformin.
Timeline
- Start
- 2006-11
- Primary completion
- 2007-02
- Completion
- 2007-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Alogliptin | Unknown | 25 mg | Oral |
| Subject | SYR-619 | Unknown | 12.5 mg | Oral |
| Subject | SYR-619 | Unknown | 50 mg | Oral |
| Subject | SYR-619 | Unknown | 100 mg | Oral |
| Subject | SYR-619 | Unknown | 200 mg | Oral |